EMA wants docs to stop pre­scrib­ing Eli Lil­ly’s can­cer drug Lartru­vo — and here's why

Just a few days af­ter Eli Lil­ly’s em­bar­rass­ing ad­mis­sion that its quick-to-mar­ket soft tis­sue sar­co­ma drug Lartru­vo (olara­tum­ab) flopped in a Phase III con­fir­ma­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER